In this study, we investigated the mechanism for proteolytic processing of the Sre1 transcription factor in
C. neoformans serotype A. Multiple lines of evidence suggest that Stp1 is a conserved Site-2 protease required for Sre1 activation. First, Stp1 shows ~14% identity and 22% similarity to the human Site-2 protease ortholog and predicted catalytic residues are conserved (). Second,
stp1Δ cells fail to accumulate the activated N-terminal transcription factor domain of Sre1 under low oxygen (). Third, when conserved catalytic residues of Stp1 were mutated, Sre1 processing was defective and cells displayed growth phenotypes similar to
sre1Δ and
stp1Δ strains (). Importantly, ectopic expression of the soluble N-terminus of Sre1 in
stp1Δ cells rescued growth on CoCl
2, demonstrating that Stp1 is required for Sre1 transcriptional activity (). Finally, using Sre1 C-terminal truncations as size standards, we determined that Sre1N cleavage occurs between amino acids 501–535. Thus, proteolytic cleavage likely occurs within the first transmembrane segment of Sre1 at a position close to that determined for mammalian SREBP-2 () (
Duncan et al., 1998). The Site-2 protease cleavage site of mammalian SREBP is not present in the first transmembrane segment of
C. neoformans Sre1. However, previous studies demonstrated that the mammalian Site-2 protease cleavage site in SREBP can be mutated without affecting cleavage (
Ye et al., 2000a). Taken together, these data indicate that
C. neoformans Stp1 is a functional Site-2 protease required for the proteolytic activation of Sre1. Notably,
Schizosaccharomyces pombe and
Aspergillus fumigatus have functional SREBP transcription factors, but lack an identifiable Stp1 homolog, suggesting alternate mechanisms for Sre1 cleavage in these fungi (
Willger et al., 2008;
Hughes, Todd, and Espenshade, 2005).
In addition to its role in Sre1 cleavage, Stp1 is required to maintain levels of the full-length precursor form of Sre1. While Sre1 precursor is present in
stp1Δ cells, levels are greatly reduced under both normoxic and hypoxic conditions (). Based on our results, the decrease is not due to changes in
SRE1 transcription since
SRE1 expression is unchanged in
stp1Δ cells under normoxic conditions (). Recent studies in the fission yeast
Schizosaccharomyces pombe demonstrated that in the absence of the Sre1 binding partner Scp1, Sre1 precursor is degraded via the ER-associated degradation (ERAD) pathway, leading to reduced Sre1 precursor (
Hughes, Nwosu, and Espenshade, 2009). While
C. neoformans stp1Δ cells contain wild-type amounts of Scp1 (
Fig. S3), Sre1 in the ER may not bind Scp1 due to mislocalization of Scp1. Preliminary studies to address this hypothesis employed the drug brefeldin A (BFA), which causes mixing of ER and Golgi compartments (
Lippincott-Schwartz et al., 1989). Interestingly, treating
stp1Δ cells with BFA restored Sre1 precursor to wild-type levels (
Fig. S4). While further experimentation is required, these data are consistent with a model in which the localization of Scp1 is altered in
stp1Δ cells. Consequently, free Sre1 in the ER may be degraded by ERAD. In addition, Sre1 nuclear form was decreased in wild-type cells treated with brefeldin A, suggesting that Stp1 is unable to cleave Sre1 under these conditions.
Cleavage of mammalian SREBP by the Site-2 protease requires prior cleavage in the lumenal loop of SREBP by the Site-1 protease, a subtilisin-like serine protease (
Espenshade and Hughes, 2007). This intermediate cleavage product can be detected by SREBP immunoblot and accumulates in Site-2 protease deficient cells (
Rawson et al., 1997). Despite the conservation of Stp1 function and cleavage position, we tested several candidate Site-1 protease homologs and have not identified a protein involved in Sre1 processing (data not shown). Furthermore, we have been unable to identify an intermediate form of Sre1 in
stp1Δ cells by immunoblot, indicating that perhaps no Site-1 protease cleavage exists or that the intermediate cleavage product is unstable.
The
Cryptococcus neoformans species complex is classified into 5 serotypes (A, B, C, D, A/D), each with distinct disease characteristics. Serotypes A and D cause the majority of human disease, primarily in immunocompromised patients (
Mitchell and Perfect, 1995;
Bennett, Kwon-Chung, and Howard, 1977). Our previous work showed that in
C. neoformans serotype D cells
SRE1 is essential for virulence in a mouse model of infection (
Chang et al., 2007). Here, our virulence studies using
C. neoformans serotype A strains confirmed previous results from Chun
et al. and demonstrated that
sre1Δ and
stp1Δ cells show attenuated virulence, indicating that Sre1 activation is required for full virulence (
Chang et al., 2007). Further experiments are required to determine whether the virulence phenotypes observed in the
sre1Δ and
stp1Δ strains are due to a decrease in melanin synthesis. However, Chun
et al. argued that this is unlikely since
sre1Δ and
stp1Δ cells showed decreased colonization in both the lungs and brains of infected mice (
Chun, Liu, and Madhani, 2007), while
lac1 mutant cells, with no melanin synthesis, showed decreased colony formation only in the brain (
Chun, Liu, and Madhani, 2007).
To investigate the differences in the virulence phenotypes of
sre1Δ cells between serotype A and D strains, we determined Sre1-dependent gene expression in serotype A cells and compared these with our previous data for serotype D (
Chang et al., 2007). Interestingly, serotype A Sre1 regulates similar but not identical genes as serotype D Sre1 (). Similar to serotype D Sre1, serotype A Sre1 is required for hypoxic expression of genes encoding ergosterol biosynthetic enzymes. However, serotype A Sre1 is largely not required for hypoxic expression of genes required for iron and copper acquisition. This is in contrast to serotype D Sre1, which regulates siderophore, iron and copper transporters (
Chang et al., 2007). Given that iron acquisition in the host is a virulence requirement for many pathogens, serotype D cells lacking
SRE1 may be limiting for iron, but not serotype A cells (
Howard, 1999;
Jung and Kronstad, 2008). Thus, differences in regulation of metal homeostasis between serotypes A and D may explain the differential requirement for Sre1 in virulence. Continued investigation and comparison of Sre1 in serotypes A and D may provide insight to the mechanism of
C. neoformans adaptation to the host environment.
Site-2 proteases are highly conserved throughout evolution, and many substrates other than SREBPs exist, including the stress response transcription factor ATF6 (
Rawson and Li, 2007;
Makinoshima and Glickman, 2006;
Ye et al., 2000b). While a clear
C. neoformans ATF6 homolog has not been identified, we investigated whether Stp1 acts on other transcriptional regulators by comparing Stp1 and Sre1-dependent gene expression. In our analysis, we found 258 genes regulated by Stp1 and not Sre1 (, ). Stp1-dependent only genes included 28 genes involved in translation and ribosome biogenesis. Although the fold change in gene expression was significant, it was less than two-fold (). Overall, the genes with the highest fold difference between wild-type and
stp1Δ strains were also dependent upon Sre1. These data indicate that the primary transcriptional regulator controlled by Stp1 under the conditions tested is Sre1. Importantly, Sre1 is the most important substrate of Stp1 for virulence, due to the fact that we observed similar virulence phenotypes in the
sre1Δ and
stp1Δ strains ().
Sre1 is activated under low oxygen and functions as a hypoxic transcription factor in fungi (
Chang et al., 2007;
Chun, Liu, and Madhani, 2007;
Willger et al., 2008;
Hughes, Todd, and Espenshade, 2005). In fission yeast, Sre1 is a major regulator of hypoxic gene expression controlling two-thirds of genes highly regulated under low oxygen, and
sre1Δ cells show a severe low oxygen growth defect (
Hughes, Todd, and Espenshade, 2005;
Todd et al., 2006). In contrast,
sre1Δ strains from
C. neoformans serotype A and D display mild growth defects under hypoxia (
Chang et al., 2007;
Chun, Liu, and Madhani, 2007). Our analysis of
C. neoformans low oxygen gene expression in wild-type cells revealed that expression of 28% of genes (1929/6798) changed significantly after 2 hours at 3% oxygen. However, only a small subset (87/1929 or 4.5%) of these hypoxic genes required Sre1 for regulation under low oxygen. These data indicate that while activated under low oxygen,
C. neoformans Sre1 is not the principal regulator of low oxygen gene expression and that hypoxic regulators remain unidentified.
Ergosterol is an essential component of fungal cell membranes and is not present in mammalian cells (
Espenshade and Hughes, 2007). Consequently, many antifungal therapeutics target ergosterol biosynthesis including the widely-used azole class of drugs. However, issues of fungal resistance to azole drugs have become a concern, particularly in severely immunocompromised patients (
Lewis and Graybill, 2008;
Kanafani and Perfect, 2008). Due to this, azole drug regimens are frequently given in combination with other antifungals and are administered for long periods of time (
Lewis and Graybill, 2008). One proposed reason for the appearance of azole resistance in immunocompromised hosts is that azole antifungals are generally thought to be fungistatic and not fungicidal, meaning that they inhibit fungal cell growth but do not lead to cell death (
Lewis and Graybill, 2008;
Kanafani and Perfect, 2008). Consequently, fungistatic drugs may only be completely effective in individuals with normal immune function that can rapidly clear non-dividing yeast.
Our gene expression and cellular sterol composition analyses demonstrate that Sre1 regulates ergosterol biosynthetic enzymes and that Sre1 activation is essential for sterol homeostasis (). Excitingly, our studies demonstrated that itraconazole and 25-thialanosterol display fungicidal effects against sre1Δ and stp1Δ cells (). Mutant cells lost viability rapidly, with significant effects as early as three hours post-treatment (). Taken together, these results demonstrate that the Sre1 pathway is required for cellular growth and survival in the presence of sterol biosynthesis-inhibiting antifungal drugs. Given the need for fungicidal drugs, we propose that inhibitors of Stp1, Sre1, or other regulators of Sre1 function administered in combination with a sterol synthesis inhibitor could prove an effective strategy to treat cryptococcosis.